State Street’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-69,430
| Closed | -$16K | – | 4318 |
|
|
2024
Q4 | $16K | Hold |
69,430
| – | – | ﹤0.01% | 4252 |
|
|
2024
Q3 | $149K | Hold |
69,430
| – | – | ﹤0.01% | 3886 |
|
|
2024
Q2 | $358K | Buy |
69,430
+11,000
| +19% | +$57.8K | ﹤0.01% | 3645 |
|
|
2024
Q1 | $313K | Buy |
58,430
+9,000
| +18% | +$62.2K | ﹤0.01% | 3765 |
|
|
2023
Q4 | $385K | Buy |
49,430
+16,300
| +49% | +$55.8K | ﹤0.01% | 3705 |
|
|
2023
Q3 | $131K | Hold |
33,130
| – | – | ﹤0.01% | 4044 |
|
|
2023
Q2 | $104K | Hold |
33,130
| – | – | ﹤0.01% | 4228 |
|
|
2023
Q1 | $88.5K | Hold |
33,130
| – | – | ﹤0.01% | 4357 |
|
|
2022
Q4 | $119K | Sell |
33,130
-2
| -0% | -$9 | ﹤0.01% | 4317 |
|
|
2022
Q3 | $213K | Buy |
33,132
+11,950
| +56% | +$97.1K | ﹤0.01% | 4117 |
|
|
2022
Q2 | $204K | Sell |
21,182
-92,753
| -81% | -$868K | ﹤0.01% | 4188 |
|
|
2022
Q1 | $1.36M | Sell |
113,935
-959
| -0.8% | -$17.2K | ﹤0.01% | 3709 |
|
|
2021
Q4 | $3.75M | Buy |
114,894
+3,337
| +3% | +$135K | ﹤0.01% | 3374 |
|
|
2021
Q3 | $4.99M | Buy |
111,557
+11,632
| +12% | +$568K | ﹤0.01% | 3243 |
|
|
2021
Q2 | $5.45M | Buy |
99,925
+20,390
| +26% | +$1.21M | ﹤0.01% | 3204 |
|
|
2021
Q1 | $5.95M | Buy |
79,535
+6,841
| +9% | +$711K | ﹤0.01% | 2972 |
|
|
2020
Q4 | $7.89M | Sell |
72,694
-97,254
| -57% | -$8.87M | ﹤0.01% | 2756 |
|
|
2020
Q3 | $15M | Buy |
169,948
+85,433
| +101% | +$9.71M | ﹤0.01% | 2201 |
|
|
2020
Q2 | $9.01M | Buy |
84,515
+19,202
| +29% | +$1.72M | ﹤0.01% | 2476 |
|
|
2020
Q1 | $3.87M | Sell |
65,313
-2,983
| -4% | -$202K | ﹤0.01% | 2750 |
|
|
2019
Q4 | $4.72M | Buy |
68,296
+870
| +1% | +$52.8K | ﹤0.01% | 2873 |
|
|
2019
Q3 | $7M | Buy |
67,426
+11,093
| +20% | +$1.05M | ﹤0.01% | 2632 |
|
|
2019
Q2 | $5.22M | Buy |
56,333
+14,244
| +34% | +$992K | ﹤0.01% | 2797 |
|
|
2019
Q1 | $3.85M | Buy |
42,089
+1,077
| +3% | +$75K | ﹤0.01% | 2875 |
|
|
2018
Q4 | $2.28M | Buy |
41,012
+2,824
| +7% | +$215K | ﹤0.01% | 3065 |
|
|
2018
Q3 | $4.55M | Buy |
38,188
+3,011
| +9% | +$349K | ﹤0.01% | 2903 |
|
|
2018
Q2 | $3.59M | Buy |
35,177
+15,003
| +74% | +$1.86M | ﹤0.01% | 3023 |
|
|
2018
Q1 | $2.62M | Buy |
20,174
+1,110
| +6% | +$121K | ﹤0.01% | 3060 |
|
|
2017
Q4 | $1.86M | Sell |
19,064
-180
| -0.9% | -$24.2K | ﹤0.01% | 3213 |
|
|
2017
Q3 | $2.83M | Buy |
19,244
+2,294
| +14% | +$431K | ﹤0.01% | 3053 |
|
|
2017
Q2 | $2.73M | Buy |
16,950
+10,825
| +177% | +$1.7M | ﹤0.01% | 3009 |
|
|
2017
Q1 | $976K | Buy |
6,125
+1,580
| +35% | +$193K | ﹤0.01% | 3270 |
|
|
2016
Q4 | $554K | Buy |
4,545
+2,047
| +82% | +$287K | ﹤0.01% | 3376 |
|
|
2016
Q3 | $347K | Buy |
+2,498
| New | +$317K | ﹤0.01% | 3347 |
|
Other funds holding SYRS
BBA
1CM
State Street's SYRS Position: Q1 2025 in Review
State Street sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2025, closing a stake of 69,430 shares — an estimated $16K sold.
State Street first reported a position in SYRS in Q3 2016 and held it in 34 quarters. The position peaked at $15M in Q3 2020. 7 funds tracked by Wall St. Rank hold SYRS as of Q1 2025.
- State Street reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- State Street sold 69,430 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2025, an estimated $16K.
- State Street first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2016 and held it in 34 quarters.
- State Street's Syros Pharmaceuticals, Inc. Common Stock position peaked at $15M in Q3 2020.
- 7 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2025.
Based on State Street's 13F filing for Q1 2025, filed 15 May 2025.